✦ LIBER ✦

P.285 Differences in virus and host characteristics between patients with HCV genotype 2 or 3 participating in a large international study

✍ Scribed by S. Zeuzem; S. Pappas; L. Nyberg; S. Greenbloom; A. Gibas; B. Bacon; E. Godofsky; H. Harley; J. Bronowicki; A. Lin; G. Hooper; M. Shiffman

Book ID: 117770502
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 143 KB
Volume: 36
Category: Article
ISSN: 1386-6532
DOI: 10.1016/s1386-6532(06)80465-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1418 DACLATASVIR COMBINED WITH PEGINTERF

1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY

✍ Dore, G.J.; Lawitz, E.; H'ezode, C.; Shafran, S.; Ramji, A.; Tatum, H.; Taliani, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 78 KB

O.160 16 or 24 weeks of peginterferon al

O.160 16 or 24 weeks of peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with HCV genotype 2 or 3 and bridging fibrosis or cirrhosis: Results from a large, randomised multinational study (ACCELERATE)

✍ S. Zeuzem; S. Pappas; L. Nyberg; S. Greenbloom; A. Gibas; B. Bacon; E. Godofsky; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 143 KB